Abstract:Mohsen Salama, &ast Nehad Darwesh, &ast Maha Mohammad Elsabaawy, &ast Eman Abdelsameea, &ast Asmaa Gomaa, &ast Aliaa Sabry &ast Department of Hepatology and Gastroenterology, National Liver Institute, Menofia University, Shebeen El-Kom, Menofia, Egypt &astThese authors contributed equally to this work Correspondence: Asmaa Gomaa, National Liver Institute, Menofia University, Shebeen El-Kom, Menofia, Egypt, Tel +20-1006157160, Email Purpose: This research was designed to determine the long-term outcomes in patients with liver cirrhosis who achieved sustained virological response (SVR) after direct-acting anti-viral drugs (DAAs) based regimens. Patients and Methods: This study involved 193 patients with HCV-related cirrhosis who had previously completed DAAs regimens and accomplished SVR. Clinical, laboratory, and radiological features at the first and 3rd-year follow-up after the end of treatment were analyzed. Overall survival (OS) and incidence of liver decompensation or hepatocellular carcinoma (HCC) were determined at the 5-year follow-up. Results: About 68.4% of our patients with HCV-related cirrhosis were males and their mean age was 54.8 ± 7.7 years. Follow-up at the first and the 3rd-year showed significant improvements in albumin ( P = 0.001), liver enzymes ( P = 0.001), alpha-fetoprotein (AFP) ( P < 0.001), platelet count ( P = 0.001), the model for end-stage liver disease (MELD) score ( P = 0.001 and 0.01), FIB4 and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores ( p < 0.001). The liver stiffness (LS) also significantly improved ( p = 0.001). At the 5th year, the mean OS was 58.3 months, with 14.5% and 17.6% of patients developing de-novo HCC and decompensation, respectively. The mean OS at the 5th-year follow-up was shorter in patients who developed HCC and those with liver decompensation ( p = 0.001). Alfa-fetoprotein and LS are predictive factors for HCC development. Conclusion: Despite achieving SVR, continuous surveillance for HCC and new-onset decompensation is mandatory in patients with liver cirrhosis. Keywords: long-term outcomes, cirrhotic patients, sustained virological response, DAAs Chronic infection with hepatitis C virus (HCV) persists as a significant universal public health issue, which affects almost seventy-one million individuals who are persistently infected with HCV. 1 Chronic inflammation of the liver causes fibrosis, which can eventually develop into cirrhosis. This increases the vulnerability of individuals to hepatic decompensation, HCC, and mortality related to hepatic disease. 2,3 During the interferon (IFN) era, achieving SVR was linked to better long-term results and a reduced risk of liver-related diseases, such as HCC. 2 However, even the most efficient IFN therapy plans were hindered by extended periods of treatment, significant adverse effects, and limited effectiveness in combating the virus. Furthermore, the primary determinant is the likelihood of achieving positive therapeutic outcomes in individuals with advanced liver disease for whom IFN-based treatment may not be suitable. 4 The implementation of IFN-free DAAs has significantly increased SVR rates in all patient groups, including those with severe liver disease or prior treatment experience, consequently altering the progression of chronic HCV infections. The SVR rates achieved with DAA regimens surpass 95%, demonstrating an outstanding safety and tolerability profile. This has expanded the range of individuals eligible for HCV treatment, along with those who have successfully been cured. 5–9 Noteworthy, Egypt has shifted from having the highest rates of HCV infection globally to one of the lowest by lowering the prevalence from 10% to 0.38% in just over a decade. It has diagnosed 87% of inhabitants having chronic hepatitis C and offered treatment to 93% of those diagnosed and was awarded the "gold tier" status on the path to elimination of hepatitis C, as per WHO criteria. The treatment was offered to a large number of patients including those with advanced liver disease and cirrhosis, which raised attention about the long term consequences on those patients, especially decompensation events and risk of HCC. 10 Research on the immediate effects of DAA therapy in advanced liver disease patients has shown enhancements in the MELD score and other biochemical markers of liver function. 11–14 Nevertheless, it remains unclear how the elimination of a virus and potential improvements in liver function may be connected to the development of long-term clinical outcomes in real-w -Abstract Truncated-

Liver-related outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients

Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?

Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis

Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin

A Matter of Follow-Up or Something Else?

Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs)

Sustained Virologic Response (SVR) to Direct-Acting Antiviral (DAA) Therapy in Patients with Chronic Hepatitis C Virus (HCV) Infection and Hepatocellular Carcinoma (HCC): a Systematic Review and Meta-Analysis

Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C

Liver stiffness and spleen stiffness predict distinct liver-related events after hepatitis C eradication with direct-acting antivirals

Ten‐year Follow‐up Analysis of Chronic Hepatitis C Patients after Getting Sustained Virological Response to Pegylated Interferon‐α and Ribavirin Therapy

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C

Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure

Long-term follow-up study of genotype 1 patients with HCV-related compensated cirrhosis treated with pegylated interferon alpha-2a and ribavirin

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis

Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).

Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure